The short answer
After breast cancer, systemic hormone therapy is generally not recommended, especially for hormone receptor-positive disease. Effective non-hormonal options include certain SNRIs and SSRIs, gabapentin, oxybutynin and the newer neurokinin-receptor medicines, along with cognitive behavioral therapy. Vaginal symptoms usually start with non-hormonal moisturizers; low-dose vaginal estrogen is sometimes considered after discussion with your oncologist.
No advertising or analytics trackers run on Specialized Care pages. Reading them is never linked to your identity. Our privacy pledge
Why breast cancer treatment causes menopause symptoms
Many breast cancers are fueled by estrogen, so treatment often lowers or blocks it. Chemotherapy can stop the ovaries working, ovarian suppression does so deliberately, tamoxifen blocks estrogen in breast tissue, and aromatase inhibitors lower estrogen throughout the body. The result can be sudden, intense hot flashes, sleep disruption, joint aches and vaginal dryness, sometimes at a younger age than natural menopause.
Symptoms are a common reason people stop endocrine therapy early. Treating them well can help you stay on the cancer treatment your oncologist recommends.
Non-hormonal options for hot flashes
| Option | Notes |
|---|---|
| Venlafaxine or desvenlafaxine (SNRI) | Well studied in survivors; generally compatible with tamoxifen |
| Citalopram or escitalopram (SSRI) | Often chosen with tamoxifen; paroxetine and fluoxetine usually avoided |
| Gabapentin | Helpful when night sweats disrupt sleep; may cause drowsiness |
| Oxybutynin | Reduces hot flashes; dry mouth common; caution about long-term cognitive effects in older adults |
| Fezolinetant (Veozah) | FDA-approved for menopausal hot flashes; requires liver monitoring; limited data specifically in survivors |
| Elinzanetant (Lynkuet) | FDA-approved for menopausal hot flashes; studied in women on endocrine therapy, but that use was not FDA-approved at our last update |
| Cognitive behavioral therapy and clinical hypnosis | Evidence-based, no drug interactions |
Vaginal and urinary symptoms
Dryness, pain with sex and urinary symptoms are common, especially with aromatase inhibitors. ACOG recommends starting with non-hormonal vaginal moisturizers and lubricants, pelvic floor therapy and dilators where helpful. If symptoms persist, low-dose vaginal estrogen may be considered after a shared decision with your oncologist; very little is absorbed, but the decision is individual, particularly while taking an aromatase inhibitor.
Bone, heart and long-term health
- Aromatase inhibitors accelerate bone loss: a baseline bone density (DXA) scan and follow-up are usually recommended
- Bone-protective medicines may be offered by your oncology team
- Tamoxifen carries a small increased risk of blood clots and uterine changes; report unusual bleeding
- Heart health matters after some chemotherapy and radiation; keep blood pressure, cholesterol and glucose checked
How Kindr clinicians approach care
Kindr clinicians focus on symptom relief that fits your cancer treatment plan. Your oncology team remains in charge of cancer care; menopause plans are shared with them with your permission, and hormone-based treatments are not started without their input.
Specialized care pathway
Care that takes your history into account
A private preparation tool builds a summary for a licensed Kindr clinician. Your answers stay in your browser and are not saved or sent.
Questions, answered
Common questions
Can I take HRT after breast cancer?
+
Systemic hormone therapy is generally not recommended after breast cancer, particularly hormone receptor-positive disease. Non-hormonal medicines and therapies are usually first-line. Decisions are individual and involve your oncologist.
What helps hot flashes on tamoxifen?
+
Venlafaxine, citalopram, escitalopram, gabapentin and oxybutynin are commonly used. Paroxetine and fluoxetine are usually avoided because they can reduce tamoxifen’s effect. CBT also helps.
Is vaginal estrogen safe after breast cancer?
+
Non-hormonal moisturizers come first. If symptoms persist, ACOG says low-dose vaginal estrogen may be considered after shared decision-making with your oncologist, especially for people taking tamoxifen rather than aromatase inhibitors.
Is Lynkuet approved for women on endocrine therapy?
+
Lynkuet is FDA-approved for moderate to severe menopausal hot flashes. A separate indication for hot flashes caused by endocrine therapy was under FDA review, not approved, at our last update.
Do aromatase inhibitors cause bone loss?
+
Yes. They lower estrogen throughout the body, which speeds bone loss. A bone density scan at the start and during treatment is usually recommended.
WRITTEN & MEDICALLY REVIEWED BY
Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team, led by Kevin Wolfe, CMO
Kindr’s clinical content is written and reviewed by board-certified clinicians who prescribe hormone therapy every day across all 50 states — menopause-focused physicians, nurse practitioners, and pharmacists working under Kindr Health, Inc.’s organizational clinical oversight. Every page is checked against current NAMS and ACOG guidance, FDA labeling, and the primary literature before publication, then re-reviewed on a rolling schedule when guidance changes.
Organizational NPI 1609792902 · Last reviewed October 5, 2026 · Editorial policy
Educational content only — not a substitute for individual medical advice, diagnosis, or treatment.
SOURCES & REFERENCES
Every clinical claim on this page is sourced.
- The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society (2023) — Menopause (journal of The Menopause Society). pubmed.ncbi.nlm.nih.gov/?term=2023+nonhormone+therapy+position+statement+North+American+Menopause+Society
- Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-dependent Breast Cancer (Clinical Consensus) (2021) — American College of Obstetricians and Gynecologists. www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2021/12/treatment-of-urogenital-symptoms-in-individuals-with-a-history-of-estrogen-dependent-breast-cancer
- NCCN Guidelines: Survivorship (menopause and hormone-related symptoms) — National Comprehensive Cancer Network. www.nccn.org/guidelines/category_3
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society (2022) — The Menopause Society. www.menopause.org/docs/default-source/professional/nams-2022-hormone-therapy-position-statement.pdf
- LYNKUET (elinzanetant) prescribing information — DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov/dailymed/search.cfm?query=elinzanetant
- VEOZAH (fezolinetant) prescribing information — DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov/dailymed/search.cfm?query=fezolinetant